Stroke treatment with urokinase in real-world settings
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at how well the clot-busting drug urokinase works for treating acute ischemic stroke in everyday medical practice. It may help if you have had a stroke and are eligible for clot-dissolving medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a new, sudden stroke that causes weakness or trouble speaking, and brain scans show it is caused by a clot, not bleeding.
- This is your first stroke, or any previous stroke left you with no major disability (able to do daily activities on your own).
- Your doctor decides you can safely receive a clot-busting drug like urokinase or alteplase.
- You agree to take part and sign a consent form (or a family member or legal representative can agree for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
This trial tests whether adding a medicine called human urinary kallidinogenase (which improves blood flow to the brain) to standard clot-busting treatment (reteplase) helps people recover better from an acute stroke. It's for patients who arrive at the hospital within 4.5 hours of symptom onset and meet specific safety criteria.
This study tests whether a clot-busting drug called pro-urokinase can help people with a stroke in the back of the brain when given later than usual (4.5 to 9 hours after symptoms start). The goal is to see if it improves recovery and reduces disability.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.